French pharma firm Pierre Fabre has acquired several assets from the biotechnology company Igenica Biotherapeutics, based in Burlingame, CA. The agreement includes immunotherapies targeting immune checkpoints that may reverse the resistance to existing immuno therapies. The most advanced asset is currently at preclinical stage and is expected to be administered to patients in the coming 2 to 3 years. The agreement also comprises a series of early discovery targets. “This agreement is in line ...